Site Solutions Summit In The News
The following article appeared on clinpage.com on April 1, 2010
Five years ago, when Christine Pierre attempted to bring together clinical investigators and other site leaders to casually discuss their best practices, it didn't go as she'd hoped. She sent out 1,000 invitations. Representatives from ten sites showed up. "In all honesty, it was a huge failure," says Pierre, president of Baltimore area-based RxTrials, a 16-year-old site network.
And yet, the handful of site leaders met anyway for a weekend in Santa Fe dubbed the Site Solutions Summit, and dug in on annoying issues that are universal to sites, casting about for remedies. Then they went home.
But that gathering was not a failure after all. Word of the meeting spread. Other site owners, directors and investigators got jazzed about what Pierre was trying to accomplish. The Association of Clinical Research Organizations (ACRO) even contacted Pierre and said it wanted to be involved. more...
October 15-18, 2010
Site Solutions Summit
Sandpearl Resort
Clearwater Beach FL
Christine Pierre named among top 100 leaders in life-sciences industry
Christine K. Pierre, President and CEO of RxTrials, Inc., has been named to the PharmaVOICE 100, an annual list of individuals recognized for their leadership and positive contributions to the life-sciences industry.
Download a .pdf of the full press release here.
Christine Pierre quoted in the Philadelphia Inquirer 06/21/06
-the following article appeared in the Philadelphia Inquirer during the 2006 DIA Conference:
Please stop calling them drug 'trials'
Participation rates in clinical trials, uh, research studies have dropped, and the industry blames news media and legal woes.
By Thomas Ginsberg
Inquirer Staff Writer
The $10-billion-a-year clinical-drug-trial business kindly asks you to forget part of its name.
That would be the trial part. The industry, holding its annual meeting in Philadelphia this week, is trying to raise U.S. participation rates in drug studies and combat what some call negative news coverage of pharmaceutical development and marketing, notably its legal troubles. And surveys suggest trial just isn't helping.
"People view trial as litigious," said Christine K. Pierre, a patient-recruitment consultant and speaker at the weeklong convention of the Drug Information Association, a global industry clearinghouse with headquarters in Horsham. "Stop calling it a trial and your enrollment will increase."